| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 06/11/2002 | US6403597 Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| 06/11/2002 | US6403592 Serotonin reuptake inhibitors |
| 06/11/2002 | US6403591 1-azatricyclic-4-benzylpiperazines |
| 06/11/2002 | US6403587 Autoimmune diseases, acute and chronic inflammatory conditions, allergic conditions, infection associated with inflammation, viral, transplantation tissue rejection, atherosclerosis, restenosis, hiv infectivity, and |
| 06/11/2002 | US6403584 Conjunctivitis, allergic rhinitis, alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, antiinflammatory, etc |
| 06/11/2002 | US6403577 Hexamethyleneiminyl tachykinin receptor antagonists |
| 06/11/2002 | US6403573 Compounds of azetidine and pyrrolidin |
| 06/11/2002 | US6403570 Method of curing an injury to a skin surface |
| 06/11/2002 | US6403567 To stimulate mammalian coronary vasodilatation and for imaging the heart; regadenoson |
| 06/11/2002 | US6403563 Antineoplastic topoisomerase i inhibitor |
| 06/11/2002 | US6403559 C-kit ligand-based method for expanding peripheral blood cell levels |
| 06/11/2002 | US6403558 Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis |
| 06/11/2002 | US6403555 Depsipeptide and congeners thereof for use as immunosuppressants |
| 06/11/2002 | US6403381 Using chelate compound |
| 06/11/2002 | US6403361 Enzymatic method for modification of recombinant polypeptides |
| 06/11/2002 | US6403318 Fatty acid synthase mRNA binding protein |
| 06/11/2002 | US6403110 Topical treatment for oily skin |
| 06/11/2002 | US6403091 Produced by the hybridoma having atcc accession no. hb 10916. |
| 06/11/2002 | US6403089 Inhibitors of fgl2; bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer, gastrointestinal diseases and fetal loss; monoclonal and polyclonal antibodies which bind to fgl2 and prevent fibrin |
| 06/11/2002 | US6403083 Antitumor, anticancer agents; mixture containing mycelium and carrier |
| 06/11/2002 | US6403080 Methods of modulating an immune response to antigen, and cells for use in the method |
| 06/11/2002 | US6403079 Using polypeptide |
| 06/11/2002 | US6403077 Treatment regimes featuring an IL-10-containing chimeric polypeptide |
| 06/11/2002 | US6402037 Two-photon upconverting dyes and applications |
| 06/11/2002 | CA2276614C Analogs of parathyroid hormone |
| 06/11/2002 | CA2262692C Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives |
| 06/11/2002 | CA2239705C Quinazoline-4-one ampa antagonists |
| 06/11/2002 | CA2239170C Improved perfluorocarbons for biological gas exchange and method |
| 06/11/2002 | CA2232267C Novel imidazole lipoxygenase inhibitors |
| 06/11/2002 | CA2198578C Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions |
| 06/11/2002 | CA2169839C Antipsychotic method |
| 06/11/2002 | CA2152266C Methods for detection and treatment of individuals having abnormal cells expressing hla-a2/turyosinase peptide antigens |
| 06/11/2002 | CA2124218C Cytotoxic drug therapy |
| 06/11/2002 | CA2082390C Dna encoding human 5-ht1d receptors and uses thereof |
| 06/11/2002 | CA2057441C Synthetic conversion of bryostatin 2 into bryostatin 1 |
| 06/11/2002 | CA2048638C Fibroblast growth factor (fgf)-based stabilized compositions and the use thereof |
| 06/11/2002 | CA2031756C Isatine derivatives, their preparation and use |
| 06/07/2002 | CA2360127A1 Method for treating chronic obstructive pulmonary disease |
| 06/06/2002 | WO2002045431A2 Genetically engineered herpes virus for the treatment of cardiovascular disease |
| 06/06/2002 | WO2002044406A2 Projection against mycobacterial infections |
| 06/06/2002 | WO2002044404A1 Methods for diagnosing individuals with an increased risk to develop a deficiency based on mdr1 gene polymorphism |
| 06/06/2002 | WO2002044393A1 Recombinant viral and non-viral vectors containing the human urokinase plasminogen activator gene and its utilization in the treatment of various types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars |
| 06/06/2002 | WO2002044380A2 Master bone formation transcription factor: compositions and methods of use |
| 06/06/2002 | WO2002044379A2 Transforming growth factor-beta-related molecules and uses thereof |
| 06/06/2002 | WO2002044370A1 Human cervical cancer 2 protooncogene and protein encoded therein |
| 06/06/2002 | WO2002044364A2 Polypeptides involved in immune response |
| 06/06/2002 | WO2002044362A1 Method of screening remedy for diabetes |
| 06/06/2002 | WO2002044321A2 Rna interference mediating small rna molecules |
| 06/06/2002 | WO2002044320A2 Human elongase genes and uses thereof |
| 06/06/2002 | WO2002044218A1 Compound of hydroxamic acid derivative and hyaluronic acid |
| 06/06/2002 | WO2002044210A2 Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain |
| 06/06/2002 | WO2002044209A2 Cytonkine receptor zcytor19 |
| 06/06/2002 | WO2002044192A1 Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| 06/06/2002 | WO2002044187A2 Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases |
| 06/06/2002 | WO2002044183A2 Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors |
| 06/06/2002 | WO2002044179A1 1,4,5,6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof |
| 06/06/2002 | WO2002044172A1 Morpholine derivatives as antagonists of orexin receptors |
| 06/06/2002 | WO2002044170A2 Benzothiophene derivative compounds, process of preparation and use thereof |
| 06/06/2002 | WO2002044168A2 Indole-type inhibitors of p38 kinase |
| 06/06/2002 | WO2002044166A1 Substituted quinolines as antitumor agents |
| 06/06/2002 | WO2002044165A1 Quinoline derivatives as nk-3 antagonists |
| 06/06/2002 | WO2002044164A1 0ovel farnesyl protein transferase inhibitors |
| 06/06/2002 | WO2002044156A2 Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
| 06/06/2002 | WO2002044154A1 Novel compounds |
| 06/06/2002 | WO2002044153A1 4-6-diphenyl pyridine derivatives as antiinflammatory agents |
| 06/06/2002 | WO2002044152A1 Indoline derivatives and their use as 5-ht2 receptor ligands |
| 06/06/2002 | WO2002044151A1 1,4-disubstituted piperazine derivatives useful as uro-selective $g(a)1-adrenoceptor blockers |
| 06/06/2002 | WO2002044149A1 Indole and dihydroindole derivatives |
| 06/06/2002 | WO2002044142A2 Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders |
| 06/06/2002 | WO2002044141A2 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| 06/06/2002 | WO2002044137A1 Ortho-substituted and meta-substituted bis-aryl compounds, method for the production thereof, their use as a medicament, and pharmaceutical preparations containing these compounds |
| 06/06/2002 | WO2002044131A1 Substituted carboxylic acid derivatives |
| 06/06/2002 | WO2002044130A1 Substituted carboxylic acid derivatives |
| 06/06/2002 | WO2002044129A1 Substituted carboxylic acid derivatives |
| 06/06/2002 | WO2002044127A1 Substituted carboxylic acid derivatives |
| 06/06/2002 | WO2002044126A2 Bisubstituted carbocyclic cyclophilin binding compounds and theirus |
| 06/06/2002 | WO2002043807A2 Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
| 06/06/2002 | WO2002043785A2 Intraocular implants for preventing transplant rejection in the eye |
| 06/06/2002 | WO2002043775A2 Paramagnetic metal ion-based macrocyclic contrast agents |
| 06/06/2002 | WO2002043769A2 Neutral and anionic colloidal particles for gene delivery |
| 06/06/2002 | WO2002043765A2 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
| 06/06/2002 | WO2002043764A1 Behavior chemotherapy |
| 06/06/2002 | WO2002043763A2 Combination of gaba agonists and aldose reductase inhibitors |
| 06/06/2002 | WO2002043760A1 Saccharometabolism activators |
| 06/06/2002 | WO2002043752A1 Interferon therapeutic effect-potentiating agents |
| 06/06/2002 | WO2002043739A2 Dermatological formulations containing clindamycin and a zinc-salt |
| 06/06/2002 | WO2002043734A1 Novel compounds |
| 06/06/2002 | WO2002043733A1 Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease |
| 06/06/2002 | WO2002043728A1 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
| 06/06/2002 | WO2002043721A1 Treatment of statin side effects |
| 06/06/2002 | WO2002043691A1 Skin cream stimulating the surface bloodstream |
| 06/06/2002 | WO2002043664A2 Reducing cellular damage in the human body |
| 06/06/2002 | WO2002043663A2 Tetrapartate prodrugs |
| 06/06/2002 | WO2002043652A2 Anti-proliferative drugs |
| 06/06/2002 | WO2002043648A2 Compounds active at the glucocorticoid receptor ii |
| 06/06/2002 | WO2002043618A1 Methods for contemporaneous administration of levamisole and 5-fluorouracil |
| 06/06/2002 | WO2002043578A2 Determination of risk and treatment of complications of prematurity |
| 06/06/2002 | WO2002043567A2 A method of treating cancer |
| 06/06/2002 | WO2002024665A8 Arylalkane-sulfonamides having endothelin-antagonist activity |
| 06/06/2002 | WO2002020489A3 QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE |